---
title: "Arcturus to present Phase 2 ARCT-810 clinical data in OTC deficiency on Sept. 23"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299451389.md"
description: "Arcturus Therapeutics will host a virtual event on September 23, 2026, to present Phase 2 clinical data for ARCT-810 in ornithine transcarbamylase (OTC) deficiency. A summary of the results will be released prior to the presentation. The update will also cover the company’s mRNA liver therapeutics platform and its ongoing investment in rare-disease liver programs."
datetime: "2026-09-18T13:01:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299451389.md)
  - [en](https://longbridge.com/en/news/299451389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299451389.md)
generator: "portal-rs"
---

# Arcturus to present Phase 2 ARCT-810 clinical data in OTC deficiency on Sept. 23

-   Arcturus scheduled a virtual event for Sept. 23, 2026 to present Phase 2 data for ARCT-810 in OTC deficiency. \* Results have not been presented yet; a summary is slated for release ahead of the presentation. \* Update will also cover the company’s mRNA liver therapeutics platform, signaling continued investment in rare-disease liver programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180900BIZWIRE\_USPR\_\_\_\_\_20260918\_BW208396) on September 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

- [Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency](https://longbridge.com/en/news/299948643.md)
- [Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug](https://longbridge.com/en/news/300047686.md)
- [Microsoft's blazing stock comeback isn't even close to being over, analyst says](https://longbridge.com/en/news/300955443.md)
- [Can CoreWeave Stock Rally 180%? CRWV Gets Wall Street-High $250 Price Target](https://longbridge.com/en/news/300948858.md)
- [Tesla Stock Forecast: Q3 Delivery Beat Shifts Focus to Margins and AI](https://longbridge.com/en/news/300929376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**